10-Q: Integrated BioPharma Q1 Net Income Halves Amid Sales Decline

Integrated BioPharma, Inc. reported a significant drop in net income and sales for the first quarter of fiscal year 2026, primarily due to decreased volumes from major contract manufacturing customers.

Summary

• Net sales decreased by 6.8% to $12.689 million for the three months ended September 30, 2025, compared to $13.617 million in the prior year period.
• Net income for the quarter was $123,000, a 52.5% decrease from $259,000 in the same period last year.
• Operating income fell by 66.7% to $163,000 from $490,000 year-over-year.
• Gross profit decreased by 25.7% to $1.019 million, with gross margin declining to 8.0% from 10.1%.
• Cash provided by operating activities increased significantly to $1.301 million from $657,000 in the prior year.
• Working capital increased by $345,000 to $14.860 million as of September 30, 2025.
• Cash at the end of the period increased to $4.732 million from $3.615 million at June 30, 2025.

Sentiment

Score: 3

Explanation: The company experienced significant declines in net sales, gross profit, operating income, and net income. While cash from operations improved and working capital increased, the core profitability metrics show substantial deterioration, indicating operational challenges and market headwinds. The high customer concentration and inability to pass on cost increases are notable concerns.

Positives

• Net cash provided by operating activities increased significantly to $1.301 million for the three months ended September 30, 2025, up from $657,000 in the prior year.
• Working capital improved, increasing by $345,000 to $14.860 million as of September 30, 2025.
• Cash balance at the end of the period rose to $4.732 million, an increase of $1.117 million from the beginning of the quarter.
• Interest income, net, increased to $33,000 from $14,000 year-over-year.
• Selling and administrative expenses saw a slight decrease of $25,000.

Negatives

• Net sales decreased by 6.8% to $12.689 million, primarily due to reduced sales volumes in the Contract Manufacturing Segment.
• Net income more than halved, falling by 52.5% to $123,000.
• Operating income declined sharply by 66.7% to $163,000.
• Gross profit decreased by 25.7% to $1.019 million, and gross margin compressed to 8.0% from 10.1%.
• Cost of sales as a percentage of net sales increased to 92.0% for the three months ended September 30, 2025, compared to 89.9% in the prior year, indicating reduced efficiency or pricing power.
• Sales volumes to major customers Herbalife and Life Extension decreased by $307,000 and $215,000, respectively.
• Sales in the Other Business Lines Segment decreased by 18.9% due to reduced sales in MDC WHD.

Risks

• High customer concentration: Approximately 87% of consolidated net sales for the quarter were derived from two customers (Life Extension and Herbalife) in the Contract Manufacturing Segment, making the company highly vulnerable to the loss of either customer or a reduction in their demand.
• Unionized workforce: Approximately 77% of full-time employees are covered by a union contract expiring on August 31, 2026, posing potential labor relations risks.
• Inflationary pressures and tightened labor markets: These factors have negatively impacted margins, and the company may not be able to timely increase selling prices to offset rising operating costs, including tariffs, labor, and shipping.
• Economic conditions: Consumer disposable income levels and spending habits can impact customer orders, potentially reducing demand for the company's products.
• Competition: The ability to match or beat competitors' pricing for contract manufacturing services can affect revenue and market share.
• Reliance on estimates: The preparation of financial statements requires management to make estimates and assumptions that could differ from ultimate results.
• Legal proceedings: The company is subject to claims that could have a material adverse effect on liquidity, financial condition, and cash flows if an adverse outcome arises. Currently, no legal proceedings or claims are known that are believed to have a material adverse effect.

Future Outlook

Management is focusing efforts on improving operational efficiency, reducing spending, and maintaining cost structure in line with sales, while also aiming to expand its customer base. The company acknowledges that its future results are subject to various risks and uncertainties, including economic conditions, competition, and the ability to pass on increased operating costs to customers.

Management Comments

• "We are focusing our efforts to improve operational efficiency and reduce spending that may have an impact on expense levels and gross margin."
• "We will continue to focus on our core businesses and push forward in maintaining our cost structure in line with our sales and expanding our customer base."
• "We have seen a slight negative impact in our margins due to inflation and tightened labor markets as we strive to increase prices to our customers as our operating costs increase."

Industry Context

The nutraceutical industry, while generally robust, faces challenges from economic conditions impacting consumer disposable income and spending habits. Integrated BioPharma's performance reflects these pressures, particularly in its contract manufacturing segment where demand from major customers like Herbalife and Life Extension has softened. The company's struggle to increase selling prices in a timely manner amidst rising input costs (inflation, labor, shipping) is a common challenge for manufacturers in competitive markets, potentially leading to margin compression if not effectively managed.

Legal Proceedings

• The Company is subject, from time to time, to claims by third parties under various legal theories, which could have a material adverse effect on liquidity, financial condition, and cash flows if an adverse outcome arises. Currently, no legal proceedings or claims are known that are believed to have a material adverse effect.

Related Party Transactions

• Warehouse and office facilities are leased from Vitamin Realty Associates, LLC, which is 100% owned by the estate of the Company's former chairman and certain family members who are Co-Chief Executive Officers and directors. Rent expense and lease amortization costs for these leases were $363,000 for the three months ended September 30, 2025, and $328,000 for the same period in 2024.

Stakeholder Impact

• Shareholders: Negative impact due to significant decline in net income and basic/diluted EPS, potentially affecting stock valuation.
• Employees: Approximately 77% of full-time employees are covered by a union contract expiring in August 2026, indicating potential future negotiations and impact on labor costs.
• Customers: Decreased sales volumes from major customers (Life Extension, Herbalife) suggest potential shifts in their supply chain or reduced demand for their products, impacting the company's revenue.
• Suppliers: The company's inability to timely increase selling prices due to supplier price increases (tariffs, inflationary costs) could strain supplier relationships or force absorption of higher costs.
• Creditors: While liquidity appears stable with increased cash and working capital, the decline in profitability metrics could be a long-term concern for creditworthiness if not reversed.

Next Steps

• Evaluate the impact of new accounting standards (ASU 2023-09, ASU 2024-03, ASU 2025-05) on financial statements and disclosures.
• Focus on improving operational efficiency and reducing spending.
• Maintain cost structure in line with sales.
• Expand customer base.
• Manage capital expenditures, with $500,000 budgeted for fiscal year 2026.
• Negotiate new union contract by August 31, 2026.

Key Dates

Recommendation

While the company experienced a significant decline in profitability metrics (net sales, gross profit, operating income, net income) for the quarter, indicating operational headwinds and market challenges, it also demonstrated improved cash flow from operations and a stronger working capital position. The high customer concentration and inflationary pressures are notable risks. However, management's stated focus on operational efficiency, cost control, and customer base expansion, coupled with sufficient liquidity for the foreseeable future, suggests a 'hold' position. Investors should monitor the effectiveness of management's strategies to reverse the decline in profitability and mitigate customer concentration risk before considering further investment or divestment.

Keywords

Nutraceuticals, Contract Manufacturing, Vitamins, Nutritional Supplements, Herbal Products, SEC Filing, 10-Q, Financial Results, Quarterly Report, Integrated BioPharma, Customer Concentration, Supply Chain, Inflation, Operating Income, Net Sales